Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Zalcberg

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|October 17, 2003
Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiationT Leong, M Michael, K Foo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibioticsD Rischin, S P Ackland, J Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
A phase I trial of docetaxel and gemcitabine in patients with advanced cancerD Rischin, M Boyer, J Smith, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell linesJ Zalcberg, X F Hu, A Slater, et al.
Cancer Chemotherapy and Pharmacology|October 31, 2012
A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancerM Michael, J Zalcberg, P Gibbs, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trialsD Cunningham, J Zalcberg, J Maroun, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancerJ F Bishop, R Kefford, D Raghavan, et al.
British Journal of Cancer|January 14, 2010
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialN C Tebbutt, M M Cummins, T Sourjina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumoursP L R Mitchell, R Basser, M Chipman, et al.
Histopathology|July 18, 2006
KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinibM B Loughrey, M Trivett, V Beshay, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|October 17, 2003
Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiationT Leong, M Michael, K Foo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibioticsD Rischin, S P Ackland, J Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
A phase I trial of docetaxel and gemcitabine in patients with advanced cancerD Rischin, M Boyer, J Smith, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell linesJ Zalcberg, X F Hu, A Slater, et al.
Cancer Chemotherapy and Pharmacology|October 31, 2012
A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancerM Michael, J Zalcberg, P Gibbs, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trialsD Cunningham, J Zalcberg, J Maroun, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancerJ F Bishop, R Kefford, D Raghavan, et al.
British Journal of Cancer|January 14, 2010
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialN C Tebbutt, M M Cummins, T Sourjina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumoursP L R Mitchell, R Basser, M Chipman, et al.
Histopathology|July 18, 2006
KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinibM B Loughrey, M Trivett, V Beshay, et al.
Pageof 7